Atossa Therapeutics, Inc. ATOS 深 滬
等待開盤 04-15 09:30:00 美东时间
5.35
+0.040
+0.75%
華盛通- 最 高5.44
- 今 開5.30
- 成交量 3.55万股
- 最 低 5.23
- 昨 收 5.31
- 總市值 4607.08万
- 52周最高 19.35
- 市盈率 靜 --
- 換手率 0.41%
- 52周最低 3.76
- 委 比 9.26%
- 總股本 861.14万
- 歷史最高 33480.00
- 量 比 0.59
- 振 幅 3.95%
- 歷史最低 5.23
- 每 手 1
- 風險率 3.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 大砍54%！大摩下调Robinhood 目标价从147降至95美元；星座品牌酒业(STZ)获8家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9.5美元升至9.75美元；Citizens：维持戴夫"跑赢大市"评级，目标价从310美元升至335美元
04-13 14:07
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Lowers Price Target to $24
Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and lowers the price target from $120 to $24.
04-10 17:36
美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $25
HC Wainwright & Co. analyst Emily Bodnar maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7 to $25.
03-26 20:08
Atossa Therapeutics Q4 EPS $(0.03) Beats $(0.07) Estimate
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.07) by 55.22 percent. This is a 88 percent increase over losses of $(0.25) per share from
03-26 05:44
Atossa Therapeutics Presents Oral Clinical Update On (Z)-endoxifen At MDA Clinical & Scientific Conference
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare disease indications with significant unmet need,
03-12 20:12
Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk
The latest update is out from Atossa Therapeutics ( ($ATOS) ). On February 17, ...
02-18 07:12
Atossa Therapeutics Issues 2026 Outlook and Strategic Update
Atossa Therapeutics ( ($ATOS) ) has shared an update. On February 11, 2026, Ato...
02-11 22:23
Atossa Therapeutics Completes Reverse Stock Split
Atossa Therapeutics Completes Reverse Stock Split Atossa Therapeutics Inc. has completed a reverse stock split, effective February 2, 2026. The move is intended to help the company regain compliance with Nasdaq listing requirements. Disclaimer: This news brief was created by Public Technologies (PUB
02-11 21:31
